Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 23;13:799988. doi: 10.3389/fimmu.2022.799988

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Chen, Du, Li, Ying, Lu, Shen, Gao, Yi, Xia, Sui and Shu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Association of HER2 mutation with immunotherapy outcomes in the pooled immunotherapy cohort. (A) Objective response rate (ORR) and disease control rate (DCR) according to HER2 mutation status and stratified by immune checkpoint inhibitors. Differences between subgroups were compared using the Chi-square or Fisher’s exact tests. (B) Overall survival (OS) according to HER2 mutation status. (C) Hazard ratios of genes with mutations that were significantly associated with OS in univariate Cox models in HER2-mutated tumors. (D) OS according to co-mutations (Co-Mut). Mut: mutation; WT: wild-type. The Cox proportional hazards model was used to evaluate the effects of HER2 mutations or co-mutations on survival.